Evrysdi, an eating spinal muscular atrophy treatment, can be prescribed at hospitals and is still non-reimbursement. According to related industries, Roche Korea's Spinal Muscular Atrophy treatment passed through D.C. at medical institutions such as Severance Hospital, Seoul National University Hospital, Yangsan Pusan National University Hospital, and Yongin Severance Hospital. Evrysdi, which was approved in Korea in November 2020, was first approved for "adult and infant SMA patients for more than 2 months." On top of that, the U.S. recently expanded the scope of administration to infants under 2 months of age in the United States. Evrysdi, the first oral option as an SMA treatment, has the advantage of being able to